Study-related adverse events. by Benjamin R. Lewis (22279166)

“…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”

Adverse cardiovascular events by immune checkpoint inhibitor. by Jennifer M. Kwan (3350321)

Subjects:

Distribution of cases and adverse events associated with metformin. by Mengsi Peng (12882734)

Subjects:

Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

Subjects:

Adverse event list. by Stefan Halbherr (21353882)

“…No statistically significant improvements were seen in the Montreal Cognitive Assessment (MoCA) (mean decrease −0.73; 95% CI; −2.1, 0.62; <i>p</i> = 0.255), Epworth Sleepiness Scale (mean increase 0.09; 95% CI; −2.6, 2.8; <i>p</i> > 0.999), Beck Depression Inventory (BDI) (mean decrease −1.27; 95% CI; −3.8, 1.3; <i>p</i> = 0.257), and the Starkstein Apathy Scale (mean increase 0.36; 95% CI; −1.6, 2.4; <i>p</i> = 0.822). …”

Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE. by Jennifer M. Kwan (3350321)

Subjects:

Key safety measures including adverse events. by Anuja Dokras (8679261)

Forest plot showing the ratio of odds of hypothyroidism (=event) among pediatric brain cancer patients treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the ratio of odds of grade 3 anemia (=event) among pediatric patients with brain tumors treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Number of adverse reaction case reports of finasteride administration at the PT level. by Xiaoling Zhong (181270)

Subjects:

Forest plot showing the ratio of odds of acute side effects: nausea (a) and vomiting (b) (=events) among pediatric patients with brain tumors treated with PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

Subjects:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

General procedure for the synthesis of B. by Xueqin lu (22250795)

Subjects:

The trends of gene expression in the metabolism of triglycerides in liver tissue. by Xueqin lu (22250795)

Subjects:

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects:

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

Subjects:

¹H NMR spectra for kylo-0603. by Xueqin lu (22250795)

Subjects:

Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

Subjects:

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Subjects: